Phaseline

Targets › FYN

FYN (Tyrosine-protein kinase Fyn): drug programs, companies and trials

1 program from 1 company in 5 trials: 4 Phase 2, 1 Phase 3; Immunology; next expected readout Nov 2026.

Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. (UniProt, P06241)

Open in Phaseline: the race on FYN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing InnoCare Pharma TechICP-332
Spleen tyrosine kinase (SYK) inhibitor
FYNPhase 3Atopic Dermatitis; Prurigo Nodularis (PN); Plaque Psoriasis; Chronic Spontaneous Urticaria (CSU) …Nov 2026

Conditions

Atopic Dermatitis (1) Prurigo Nodularis (PN) (1) Plaque Psoriasis (1) Chronic Spontaneous Urticaria (CSU) (1) Non Segmental Vitiligo (1)

Modalities

small molecule (1)

Companies

Beijing InnoCare Pharma Tech (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.